Abstract
We propose a mathematical framework to analyze and interpret the outcomes of human challenge trials. We present plausible infection risks with HCoV-229E and SARS-CoV-2 over a wide range of infectious dose, and suggest ways to improve the design of future trials and to translate its outcomes to the general population.
One sentence summary We rephrase dose-response models in terms of heterogeneity in susceptibility in order to present the possible range of infection risks for endemic coronaviruses and SARS-CoV-2
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
FM acknowledge funding support from JSPS KAKENHI (Grant number 20J00793). This project has received funding from the European Union Horizon 2020 research and innovation programme - project EpiPose (JW and DK, Grant agreement number 101003688). This work reflects only the authors view. The European Commission is not responsible for any use that may be made of the information it contains.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study used (or will use) ONLY openly available human data that were originally published in previous studies.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All codes and analyzed data are available online at the GitHub link (https://github.com/fmiura/CoronaDR_2022).
